Climb Bio, Inc. financial data

Symbol
CLYM on Nasdaq
Location
20 William Street, Suite 145, Wellesley Hills, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.5K % -44.3%
Debt-to-equity 2.8 % +21.7%
Return On Equity -23.1 % +50.9%
Return On Assets -22.5 % +51.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 67.8M shares +1.05%
Common Stock, Shares, Outstanding 67.8M shares +1.47%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 67.6M shares +123%
Weighted Average Number of Shares Outstanding, Diluted 67.6M shares +123%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 35.9M USD +342%
General and Administrative Expense 20.2M USD +109%
Operating Income (Loss) -56.3M USD +18.9%
Nonoperating Income (Expense) 2.01M USD +35.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -46.8M USD +27.2%
Earnings Per Share, Basic 0 USD/shares +95.3%
Earnings Per Share, Diluted 0 USD/shares +95.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.7M USD -89.8%
Marketable Securities, Current 62M USD
Assets, Current 87.4M USD -61.3%
Property, Plant and Equipment, Net 314K USD
Operating Lease, Right-of-Use Asset 618K USD +2843%
Other Assets, Noncurrent 1.37M USD
Assets 192M USD -14.9%
Accounts Payable, Current 946K USD +85.9%
Employee-related Liabilities, Current 914K USD
Accrued Liabilities, Current 6.1M USD +131%
Liabilities, Current 6.21M USD +65.9%
Operating Lease, Liability, Noncurrent 417K USD
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 6.62M USD +77%
Accumulated Other Comprehensive Income (Loss), Net of Tax 318K USD
Retained Earnings (Accumulated Deficit) -259M USD -22%
Stockholders' Equity Attributable to Parent 186M USD -16.4%
Liabilities and Equity 192M USD -14.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.4M USD -748%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -42.8M USD -411%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 67.8M shares +1.47%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -58.2M USD -588%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 22.7M USD -89.8%
Deferred Tax Assets, Valuation Allowance 28.5M USD +36.6%
Deferred Tax Assets, Gross 28.6M USD +37.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -46.4M USD +27.6%
Operating Lease, Liability, Current 222K USD +122%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +13.3%
Deferred Tax Assets, Operating Loss Carryforwards 22.7M USD +32.6%
Share-based Payment Arrangement, Expense 7.62M USD +169%